<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zyus Life Sciences Corporation — News on 6ix</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation</link>
<description>Latest news and press releases for Zyus Life Sciences Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zyus-life-sciences-corporation" rel="self" type="application/rss+xml" />
<item>
<title>ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-completion-of-the-final-study-visit-by-the-last-patient-in-phase-2a-utopia-1-trial-evaluating-novel-non-opioid-pain-drug</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-completion-of-the-final-study-visit-by-the-last-patient-in-phase-2a-utopia-1-trial-evaluating-novel-non-opioid-pain-drug</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.UTOPIA-1 trial is</description>
</item>
<item>
<title>ZYUS Life Sciences Provides an Update on Its Unit Offering</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-provides-an-update-on-its-unit-offering</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-provides-an-update-on-its-unit-offering</guid>
<pubDate>Fri, 10 Apr 2026 23:49:00 GMT</pubDate>
<description>ZYUS Life Sciences Provides an Update on Its Unit Offering Canada NewsWire /NOT FO...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Closing of Debt Financing</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-debt-financing</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-debt-financing</guid>
<pubDate>Thu, 05 Mar 2026 23:15:00 GMT</pubDate>
<description>ZYUS Life Sciences Announces Closing of Debt Financing Canada NewsWire /NOT FOR DI...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-cancellation-of-life-offering-and-launch-of-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-cancellation-of-life-offering-and-launch-of-private-placement</guid>
<pubDate>Wed, 25 Feb 2026 03:39:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, today announces the Company has elected to cancel its previously announced brokered private placement offering (the "LIFE Offering"), which was originally announced on January 12, 2026 and amended and restated on February 9, 2026. As a result, no securities will be issued, and the Company will</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-filing-120000280</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-filing-120000280</guid>
<pubDate>Mon, 09 Feb 2026 12:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce that it has filed an amended and restated offering document dated February 9, 2026 (the "Amended and Restated Offering Document") with respect to the offering (the "LIFE Offering") pursuant to and in accordance with the "listed issuer financing exemption" from the prospe</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Amendment to Subleases and Promissory Note Agreement</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-amendment-043300006</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-amendment-043300006</guid>
<pubDate>Thu, 05 Feb 2026 04:33:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce it has entered into an amendment to its subleases with its landlord pursuant to which, among other things, the Company has extended the term of its existing subleases to January 31, 2030. The Company also entered into a promissory note agreement dated January 29, 2026, p</description>
</item>
<item>
<title>ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-life-135200676</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-life-135200676</guid>
<pubDate>Mon, 12 Jan 2026 13:52:00 GMT</pubDate>
<description>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that it has launched a brokered private placement of a minimum of 23,809,523 units of the Company (each a “Unit”) and up to a maxi</description>
</item>
<item>
<title>ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-reports-preliminary-results-from-ongoing-phase-2a-utopia-1-trial-evaluating-novel-non-opioid-pain-drug</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-reports-preliminary-results-from-ongoing-phase-2a-utopia-1-trial-evaluating-novel-non-opioid-pain-drug</guid>
<pubDate>Thu, 08 Jan 2026 14:23:00 GMT</pubDate>
<description>ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating No...</description>
</item>
<item>
<title>ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-provides-update-on-clinical-trial-progress-and-unit-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-provides-update-on-clinical-trial-progress-and-unit-private-placement</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement ...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-grant-of-stock-options-and-deferred-share-units</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-grant-of-stock-options-and-deferred-share-units</guid>
<pubDate>Mon, 01 Dec 2025 22:38:00 GMT</pubDate>
<description>ZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units Canada NewsW...</description>
</item>
<item>
<title>ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-first-tranche-of-unit-offering-and-issuance-of-warrants-pursuant-to-previously-announced-loan-agreements-and-promissory-note-amendment</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-first-tranche-of-unit-offering-and-issuance-of-warrants-pursuant-to-previously-announced-loan-agreements-and-promissory-note-amendment</guid>
<pubDate>Fri, 07 Nov 2025 12:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance o...</description>
</item>
<item>
<title>ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-additional-secured-loan</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-additional-secured-loan</guid>
<pubDate>Mon, 20 Oct 2025 20:04:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan Canada NewsWi...</description>
</item>
<item>
<title>WAYNE BROWNLEE PROVIDES UPDATE ON HOLDINGS OF ZYUS LIFE SCIENCES CORPORATION</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/wayne-brownlee-provides-update-on-holdings-of-zyus-life-sciences-corporation</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/wayne-brownlee-provides-update-on-holdings-of-zyus-life-sciences-corporation</guid>
<pubDate>Fri, 17 Oct 2025 23:28:00 GMT</pubDate>
<description>On October 16, 2025, Mr. Wayne Brownlee (the "acquiror") entered into an agreement in respect of a loan (the "Loan") to ZYUS Life Sciences Inc. ("ZYUS Inc."), a wholly-owned subsidiary of ZYUS Life Sciences Corporation (the "Company") pursuant to which the acquiror advanced to Zyus Inc. a total of $1.5 million in separate tranches prior to October 16, 2025. In connection with the Loan, the Company has agreed to grant 2,173,913 warrants ("Warrants") to purchase common shares of the Company ("Comm</description>
</item>
<item>
<title>BRENT H. ZETTL PROVIDES UPDATE ON HOLDINGS OF ZYUS LIFE SCIENCES CORPORATION</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/brent-h-zettl-provides-update-on-holdings-of-zyus-life-sciences-corporation-1</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/brent-h-zettl-provides-update-on-holdings-of-zyus-life-sciences-corporation-1</guid>
<pubDate>Fri, 17 Oct 2025 23:27:00 GMT</pubDate>
<description>Mr. Brent H. Zettl (the "acquiror"), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation ("ZYUS") provides updates to his holdings of Common shares ("Common Shares") in the capital of ZYUS, Common Share purchase warrants of ZYUS ("Warrants") and options to purchase Common Shares ("Options").</description>
</item>
<item>
<title>ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-secured-loan-and-amendments-to-prior-secured-promissory-note</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-corporation-announces-closing-of-secured-loan-and-amendments-to-prior-secured-promissory-note</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured ...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-activation-of-two-additional-clinical-sites-in-phase-2a-utopia-1-cancer-pain-trial</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-activation-of-two-additional-clinical-sites-in-phase-2a-utopia-1-cancer-pain-trial</guid>
<pubDate>Thu, 02 Oct 2025 11:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Can...</description>
</item>
<item>
<title>ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-activates-first-clinical-site-and-enrolls-first-patient-in-phase-2a-utopia-1-cancer-pain-trial</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-activates-first-clinical-site-and-enrolls-first-patient-in-phase-2a-utopia-1-cancer-pain-trial</guid>
<pubDate>Tue, 26 Aug 2025 11:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 C...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-second-tranche-of-unit-offering</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-second-tranche-of-unit-offering</guid>
<pubDate>Sat, 16 Aug 2025 00:00:00 GMT</pubDate>
<description>ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering Canada NewsWire...</description>
</item>
<item>
<title>ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-first-tranche-of-unit-offering</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-announces-closing-of-first-tranche-of-unit-offering</guid>
<pubDate>Tue, 29 Jul 2025 23:18:00 GMT</pubDate>
<description>ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering Canada NewsWire ...</description>
</item>
<item>
<title>ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial</title>
<link>https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-strengthens-clinical-leadership-with-appointment-of-chief-medical-officer-to-support-phase-2-oncology-pain-trial</link>
<guid isPermaLink="true">https://6ix.com/company/zyus-life-sciences-corporation/news/zyus-life-sciences-strengthens-clinical-leadership-with-appointment-of-chief-medical-officer-to-support-phase-2-oncology-pain-trial</guid>
<pubDate>Tue, 15 Jul 2025 11:00:00 GMT</pubDate>
<description>Experienced hematologist-oncologist to lead strategic and medical oversight of clinical developme...</description>
</item>
</channel>
</rss>